-
1 Comment
Hangzhou Tigermed Consulting Co.,Ltd is currently in a long term uptrend where the price is trading 11.4% above its 200 day moving average.
From a valuation standpoint, the stock is 292.5% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 37.8.
Hangzhou Tigermed Consulting Co.,Ltd's total revenue rose by 15.5% to $892M since the same quarter in the previous year.
Its net income has increased by 37.7% to $432M since the same quarter in the previous year.
Finally, its free cash flow grew by 152.9% to $471M since the same quarter in the previous year.
Based on the above factors, Hangzhou Tigermed Consulting Co.,Ltd gets an overall score of 4/5.
| Sector | Healthcare |
|---|---|
| Industry | Diagnostics & Research |
| ISIN | CNE100001KV8 |
| Exchange | SHE |
| CurrencyCode | CNY |
| Market Cap | 50B |
|---|---|
| PE Ratio | 55.7 |
| Target Price | 65.748 |
| Dividend Yield | 0.2% |
| Beta | 0.68 |
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 300347.SHE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2026